Dickkopf-1 level is lower in patients with ankylosing spondylitis than in healthy people and is not influenced by anti-tumor necrosis factor therapy
- Authors
- Kwon, Seong-Ryul; Lim, Mie-Jin; Suh, Chang-Hee; Park, Shin-Goo; Hong, Yeon-Sik; Yoon, Bo-Young; Kim, Hyoun-Ah; Choi, Hyo-Jin; Park, Won
- Issue Date
- Aug-2012
- Publisher
- SPRINGER HEIDELBERG
- Keywords
- Dickkopf-1; Ankylosing spondylitis; TNF blocker; Osteocalcin; Osteoprotegerin; CTX-1; BASDAI
- Citation
- RHEUMATOLOGY INTERNATIONAL, v.32, no.8, pp.2523 - 2527
- Journal Title
- RHEUMATOLOGY INTERNATIONAL
- Volume
- 32
- Number
- 8
- Start Page
- 2523
- End Page
- 2527
- URI
- https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/16260
- DOI
- 10.1007/s00296-011-1981-0
- ISSN
- 0172-8172
- Abstract
- (1) To compare the serum levels of Dickkopf-1 (DKK-1) and bone biomarkers in patients with ankylosing spondylitis (AS) and healthy controls. (2) To examine the effects of anti-tumor necrosis factor-alpha (TNF-alpha) therapy for 3 months on bone biomarkers in patients with AS. We measured the levels of DKK-1, osteocalcin, osteoprotegerin, and C-terminal telopeptide of type I collagen (CTX-1) in patients with AS and in healthy controls at baseline and 3 months after initiating anti-TNF-alpha therapy in AS patients. Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) scores were also measured before and after anti-TNF-alpha therapy in AS patients. Serum levels of DKK-1 were significantly lower in the AS patients than in the controls (P < 0.0001). Osteocalcin and osteoprotegerin levels were significantly higher in the AS patients than in the controls (P < 0.0001). Serum levels of DKK-1 were not changed after the 3-month anti-TNF-alpha therapy. Osteocalcin level increased (P < 0.0001), osteoprotegerin level and BASDAI scores decreased (P = 0.025 and P < 0.0001, respectively) significantly after the 3-months anti-TNF-alpha therapy. Serum DKK-1 level was lower in patients with AS than in healthy controls and did not change after 3 months of anti-TNF-alpha therapy in the AS patients despite the marked improvement in BASDAI scores. These findings suggest the low serum DKK-1 level is related to the pathogenesis of new bone formation in AS, which is resistant to TNF-alpha blocking therapy.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 의과대학 > 의학과 > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/16260)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.